Gilead Sciences Inc. (GILD)
NASDAQ: GILD
· Real-Time Price · USD
112.43
0.70 (0.63%)
At close: Jul 02, 2025, 10:36 AM
0.63% (1D)
| Bid | 112.42 |
| Market Cap | 139.86B |
| Revenue (ttm) | 28.73B |
| Net Income (ttm) | 5.96B |
| EPS (ttm) | 7.74 |
| PE Ratio (ttm) | 14.53 |
| Forward PE | 12.94 |
| Analyst | Buy |
| Ask | 112.45 |
| Volume | 747,158 |
| Avg. Volume (20D) | 10,590,408.3 |
| Open | 111.79 |
| Previous Close | 111.73 |
| Day's Range | 111.09 - 112.78 |
| 52-Week Range | 66.01 - 119.96 |
| Beta | 0.31 |
About GILD
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol GILD
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for GILD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Gilead Sciences Inc. is scheduled to release its earnings on Aug 7, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+0%
GILD stock has given up its prior gain. Gilead sha...
Unlock content with
Pro Subscription
1 week ago
+0%
Gilead shares are trading higher after the company received FDA approval for Yeztugo, the first and only twice-yearly injectable for HIV pre-exposure prophylaxis
